Nicotinic acetylcholine receptor alpha-5 subunit (α5 nAChR)

The **Nicotinic acetylcholine receptor alpha‑5 subunit** is a protein encoded by the *CHRNA5* gene that forms part of neuronal nicotinic acetylcholine receptors (nAChRs), which are pentameric ligand-gated ion channels permeable to cations such as sodium and calcium. The α5 subunit does not form functional receptors on its own but co‑assembles with other nAChR subunits—most commonly with α3β4 or α4β2—to create heteromeric complexes found throughout the central nervous system. While it does not directly participate in ligand binding, its presence modifies key properties including agonist sensitivity/potency, desensitization kinetics, calcium permeability, membrane trafficking/localization, and downstream signaling. α5-containing nAChRs play important roles in regulating synaptic transmission—especially dopaminergic and GABAergic neurotransmission—and have been implicated in pain regulation as well as neurodevelopmental processes critical for attention circuitry maturation. Genetic variation at *CHRNA5* is strongly linked to nicotine addiction risk; altered expression/function has also been associated with cancer susceptibility and several neuropsychiatric conditions including schizophrenia and autism spectrum disorder. Therapeutically relevant ligands include endogenous acetylcholine as well as exogenous agents like nicotine; antagonists such as DhβE can be used experimentally to probe function. Because it acts mainly via modulation rather than direct activation/inhibition sites on drugs themselves—and given its auxiliary role—the therapeutic targeting strategy often involves influencing overall nAChR assembly/composition rather than selective blockade/activation.[1][3][4]

Other names

Neuronal acetylcholine receptor subunit alpha-5Alpha-5 nicotinic acetylcholine receptorα5 receptorCHRNA5

Drugs targeting this molecule act primarily by modulating ligand-gated cation channel activity through allosteric or orthosteric mechanisms, affecting neuronal excitability, neurotransmitter release, and downstream signaling pathways. The presence of the α5 subunit can alter potency/efficacy, desensitization rates, calcium permeability, and trafficking/localization of the pentameric nAChR complex.